CPK850
CCPK850X2202
Phase 2 small_molecule active
Quick answer
CPK850 for Retinitis pigmentosa caused by biallelic mutations in the RLBP1 gene is a Phase 2 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Retinitis pigmentosa caused by biallelic mutations in the RLBP1 gene
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active